NEW AMSTERDAM SCIENCES

New Amsterdam Sciences (NAS) is a clinical-stage bioscience company focused on the research, development and licensing of small molecule antioxidant SOD mimetics and peptide analogues of Substance P. The company's lead compound, NAS150, is being pursued for indications with the underlying conditions driven by oxidative stress (ROS) mediated inflammation. The company's current focus is its' phase 2 candidate for COVID-19. Other indications the company is pursuing are Multiple Sclerosis, Rheumatoid Arthritis, Pneumonia, Influenza as well as Progressive Supranuclear Palsy, Idiopathic Pulmonary Fibrosis, and Radiation-Induced Lung Injury. New Amsterdam Sciences is devoted to developing products with not only commercial value but having governmental appeal, with a focus on mass casualty biodefense applications... New Amsterdam Sciences is committed to the fight, Our Fight Against the Rapidly Evolving COVID-19 Pandemic... New Amsterdam Sciences develops novel, safe and effective therapies..

Also known as: New Amsterdam Sciences, Inc.

Primary location: Binghamton United States